Found: 5
Select item for more details and to access through your institution.
Vision loss in glioblastoma: Disease mimicking presumed therapeutic toxicity.
- Published in:
- Neuro-Oncology Practice, 2018, v. 5, n. 4, p. 223, doi. 10.1093/nop/npx037
- By:
- Publication type:
- Article
Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide.
- Published in:
- Frontiers in Oncology, 2018, p. N.PAG, doi. 10.3389/fonc.2018.00451
- By:
- Publication type:
- Article
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
- Published in:
- Neuro-Oncology, 2017, v. 19, n. 3, p. 394, doi. 10.1093/neuonc/now189
- By:
- Publication type:
- Article
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
- Published in:
- Neuro-Oncology, 2015, v. 17, n. 12, p. 1589, doi. 10.1093/neuonc/nov064
- By:
- Publication type:
- Article